GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conatus Pharmaceuticals Inc (NAS:CNAT) » Definitions » Interest Paid

Conatus Pharmaceuticals (Conatus Pharmaceuticals) Interest Paid


View and export this data going back to 2013. Start your Free Trial

What is Conatus Pharmaceuticals Interest Paid?

Interest Paid only applicable to companies reporting Cash Flow from Operations in direct method.


Conatus Pharmaceuticals (Conatus Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
16745 West Bernardo Drive, Suite 250, San Diego, CA, USA, 92127
Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The company is developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. Conatus has also been developing CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways.